PHKG2 Antibody
Description
PHKG2 Antibody Characteristics
PHKG2 antibodies are typically polyclonal reagents developed through immunization with recombinant protein fragments or synthetic peptides corresponding to specific PHKG2 epitopes. Key specifications from commercial products include:
These antibodies demonstrate consistent performance across multiple experimental platforms, with validation data showing clear detection of PHKG2 at its expected molecular weight in target tissues like liver and testis .
Biological Significance of PHKG2
PHKG2 serves as the catalytic subunit of phosphorylase kinase, playing essential roles in:
-
Glycogenolysis regulation through glycogen phosphorylase activation
Recent studies reveal PHKG2's dual role in disease pathogenesis:
Protective Function:
-
High PHKG2 expression correlates with improved survival in lung adenocarcinoma
-
Enhances radiosensitivity in non-small cell lung cancer (NSCLC) by increasing intracellular iron levels 1.8-fold post-radiation
Pathological Involvement:
Table 1: PHKG2 in NSCLC Radiosensitivity Studies
| Experimental Model | PHKG2 Manipulation | Radiation Response Change | Ferroptosis Markers |
|---|---|---|---|
| A549 cell line (in vitro) | Overexpression | LD50 decreased 32% | MDA ↑ 2.1x, 4-HNE ↑ 1.9x |
| NCI-H2170 xenografts | Knockdown | Tumor growth rate ↑ 58% | Mitochondrial depolarization ↓ 67% |
| Clinical NSCLC samples | Natural expression | 5-year survival: High vs Low = 44% vs 19% | Tissue iron ↑ 2.4x |
Mechanistic insights demonstrate PHKG2's regulation through the NRF2/PHKG2 axis:
-
NRF2 acts as transcriptional repressor, reducing PHKG2 expression 3.5-fold in radioresistant cells
-
PHKG2 overexpression increases ferritinophagy flux by 180% through NCOA4-mediated pathways
-
Combined NRF2 inhibition and PHKG2 activation reduces tumor volume 72% vs controls in vivo
Therapeutic Implications
Current research directions focus on:
Product Specs
Target Background
- These cases contribute to our current understanding of the clinical variability in patients with PHKG2 mutations. Long-term studies, which include follow-up of these patients into adulthood, are needed to further elucidate this variability. PMID: 24389071
- Patients with PHKG2 mutations present with a severe hepatic phenotype within the heterogeneous GSD IX disorder. A defect in PHKG2 should be considered in patients suspected of having glycogenosis, particularly when significant liver fibrosis and cirrhosis are present. PMID: 24326380
- PHKG2 mutations have been identified as a cause of Glycogen storage disease type IX. PMID: 17689125
Q&A
What is PHKG2 and why is it important in cellular metabolism?
PHKG2 is the catalytic subunit of phosphorylase b kinase (PHK), which mediates neural and hormonal regulation of glycogen breakdown (glycogenolysis) by phosphorylating and activating glycogen phosphorylase. It is primarily expressed in the liver and testis tissues. Phosphorylase kinase is a polymer of 16 subunits, consisting of four each of alpha, beta, gamma, and delta subunits. The gamma subunits (including PHKG2) contain the active site of the enzyme, whereas the alpha and beta subunits have regulatory functions controlled by phosphorylation. The delta subunit (calmodulin) mediates the enzyme's dependence on calcium concentration .
PHKG2 is particularly important because mutations in this gene cause glycogen storage disease type 9C, also known as autosomal liver glycogenosis. Additionally, recent research has implicated PHKG2 in cancer biology, particularly in radiotherapy response mechanisms through regulation of ferroptosis .
What are the key differences between polyclonal and monoclonal PHKG2 antibodies for research applications?
The choice between polyclonal and monoclonal antibodies should be based on your specific experimental goals. Polyclonal antibodies often provide higher sensitivity and are more tolerant to small changes in the antigen, while monoclonal/recombinant antibodies offer superior consistency and specificity .
What are the recommended applications and dilutions for PHKG2 antibodies?
Based on the available commercial antibodies, PHKG2 antibodies have been validated for multiple applications with specific recommended dilutions:
It is recommended to titrate the antibody in each testing system to obtain optimal results, as performance can be sample-dependent .
Which positive control samples are recommended for validating PHKG2 antibody performance?
Several cell lines and tissue types have been validated as positive controls for PHKG2 antibody testing:
When selecting positive controls, consider using tissues or cell lines with known PHKG2 expression. Testis and liver tissues are particularly recommended as PHKG2 is enriched in these tissues according to current literature .
How should researchers verify PHKG2 antibody specificity?
To ensure the specificity of PHKG2 antibody detection, researchers should:
-
Molecular Weight Verification: Confirm that the observed molecular weight matches the expected size of PHKG2 (46 kDa) .
-
Multiple Detection Methods: Validate findings using at least two different detection methods (e.g., WB and IHC).
-
Positive and Negative Controls: Include known positive samples (e.g., testis or liver tissues) and negative controls.
-
Knockdown/Knockout Validation: If possible, test the antibody in PHKG2 knockdown or knockout samples to confirm specificity.
-
Peptide Competition Assay: Perform a peptide competition assay using the immunogen peptide to confirm specific binding.
-
Cross-Reactivity Testing: Test the antibody against related proteins, especially other gamma subunits of phosphorylase kinase.
The antibody specificity can be further enhanced by using antibodies targeting different epitopes of PHKG2, such as those targeting the N-terminus versus those targeting amino acids 237-406 .
How is PHKG2 implicated in cancer biology, particularly in radiotherapy response?
Recent research has uncovered a significant role for PHKG2 in radiotherapy sensitivity of non-small cell lung cancer (NSCLC):
-
NRF2/PHKG2 Axis: PHKG2 is part of the NRF2/PHKG2 signaling axis that regulates radiotherapy-induced ferroptosis in NSCLC.
-
Expression Patterns: Radiotherapy-sensitive tissues showed increased expression of PHKG2.
-
Mechanistic Role: Overexpression of PHKG2 leads to:
-
Elevated intracellular iron levels through promotion of ferritinophagy
-
Increased mitochondrial stress-dependent ferroptosis induced by radiotherapy
-
-
Transcriptional Regulation: NRF2 acts as a transcriptional repressor of PHKG2.
-
Therapeutic Implications: Targeting NRF2 upregulates PHKG2 expression and may reverse radiotherapy resistance in NSCLC by promoting iron autophagy and inducing mitochondrial dysfunction, thereby increasing radiotherapy sensitivity .
This research suggests PHKG2 antibodies may be valuable tools in studying cancer radiotherapy response mechanisms and potentially in developing biomarkers for radiotherapy sensitivity in NSCLC patients.
What role does PHKG2 play in glycogen storage diseases, and how can this be studied?
PHKG2 mutations cause glycogen storage disease type 9C (GSD9C), also known as autosomal liver glycogenosis . This connection can be investigated through:
-
Mutation Analysis: Using PHKG2 antibodies to study expression levels and localization patterns of wildtype versus mutant PHKG2 proteins.
-
Functional Studies: Examining the enzymatic activity of phosphorylase kinase in patient-derived samples versus controls.
-
Therapeutic Approaches: Recent research is exploring splice switching oligonucleotides (SSOs) to restore PHKG2 expression in glycogen storage disease IX. These SSOs can correct RNA splicing and facilitate proper gene expression, demonstrating a novel therapeutic approach for diseases caused by splicing defects .
-
Tissue-Specific Expression: Studying the differential expression and function of PHKG2 in liver versus other tissues to understand the tissue-specific manifestations of GSD9C.
-
Animal Models: Utilizing PHKG2 knockouts or disease models to study pathophysiology and test therapeutic interventions.
PHKG2 antibodies are essential tools for these investigations, particularly for protein expression studies, localization analysis, and validating the effects of therapeutic interventions on protein levels.
Troubleshooting and Quality Control
Evaluating batch-to-batch consistency is crucial for long-term research projects:
-
Reference Sample Testing: Maintain a standard positive control sample (e.g., HEK-293 cells or mouse testis lysate) to test each new batch.
-
Quantitative Analysis: Perform densitometry on Western blots to compare signal intensity across batches.
-
Consider Recombinant Alternatives: When absolute consistency is critical, consider using recombinant PHKG2 antibodies, which offer "unrivalled batch-to-batch consistency, easy scale-up, and future security of supply" .
-
Detailed Record-Keeping: Document lot numbers, performance characteristics, and optimal conditions for each batch.
-
Multiple Application Testing: If using the antibody for multiple applications, verify performance in each application with every new batch.
-
Manufacturer Communication: Contact the antibody supplier regarding any significant performance differences between batches.
By implementing these strategies, researchers can minimize the impact of batch-to-batch variation on their experimental outcomes and ensure more reliable and reproducible results when working with PHKG2 antibodies.
